RU2012108110A - Применение меланокортинов для лечения дислипидемии - Google Patents

Применение меланокортинов для лечения дислипидемии Download PDF

Info

Publication number
RU2012108110A
RU2012108110A RU2012108110/15A RU2012108110A RU2012108110A RU 2012108110 A RU2012108110 A RU 2012108110A RU 2012108110/15 A RU2012108110/15 A RU 2012108110/15A RU 2012108110 A RU2012108110 A RU 2012108110A RU 2012108110 A RU2012108110 A RU 2012108110A
Authority
RU
Russia
Prior art keywords
arg
cys
ala
trp
phe
Prior art date
Application number
RU2012108110/15A
Other languages
English (en)
Inventor
Хэзер А. ХЕЙЛЕМ
Майкл Девитт КАЛЛЕР
Original Assignee
Ипсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ипсен Фарма С.А.С. filed Critical Ипсен Фарма С.А.С.
Publication of RU2012108110A publication Critical patent/RU2012108110A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1. Способ лечения дислипидемии у субъекта, нуждающегося в этом, включающий периферическое введение эффективного количества агониста рецептора-4 меланокортина для лечения дислипидемии у указанного субъекта, нуждающегося в этом.2. Способ по п.1, где указанное лечение дислипидемии происходит в результате снижения в сыворотке уровней холестерина, триглицеридов, холестеринового липопротеина низкой плотности, свободных жирных кислот или повышения уровней холестеринового липопротеина высокой плотности, или любых сочетаний указанного.3. Способ по п.1, где указанный субъект страдает стеатозом печени.4. Способ по п.3, где указанный стеатоз печени представляет собой неалкогольную жировую болезнь печени или алкогольную жировую болезнь печени.5. Способ по п.4, где указанная неалкогольная жировая болезнь печени или алкогольная жировая болезнь печени сопровождается стеатонефритом, стеатонекрозом, воспалением печеночной доли, баллонирующей дегенерацией, фиброзом, циррозом или раком или их любой комбинацией.6. Способ по п.1, где указанный агонист рецептора-4 меланокортина, используемый для лечения дислипидемии, выбран из группы, состоящей из следующих соединений:Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NHAc-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH;Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH;Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH;D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH;D-Phe-c(Cys-His-D-Phe-Arg-Trp--Ala-D-Cys)-Thr-NH;D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH;Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH;Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH;Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH;Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys--Ala-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH;Ac-Nle-c(D

Claims (12)

1. Способ лечения дислипидемии у субъекта, нуждающегося в этом, включающий периферическое введение эффективного количества агониста рецептора-4 меланокортина для лечения дислипидемии у указанного субъекта, нуждающегося в этом.
2. Способ по п.1, где указанное лечение дислипидемии происходит в результате снижения в сыворотке уровней холестерина, триглицеридов, холестеринового липопротеина низкой плотности, свободных жирных кислот или повышения уровней холестеринового липопротеина высокой плотности, или любых сочетаний указанного.
3. Способ по п.1, где указанный субъект страдает стеатозом печени.
4. Способ по п.3, где указанный стеатоз печени представляет собой неалкогольную жировую болезнь печени или алкогольную жировую болезнь печени.
5. Способ по п.4, где указанная неалкогольная жировая болезнь печени или алкогольная жировая болезнь печени сопровождается стеатонефритом, стеатонекрозом, воспалением печеночной доли, баллонирующей дегенерацией, фиброзом, циррозом или раком или их любой комбинацией.
6. Способ по п.1, где указанный агонист рецептора-4 меланокортина, используемый для лечения дислипидемии, выбран из группы, состоящей из следующих соединений:
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trpß-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;
Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-ß-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-ß-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-ß-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-ß-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;
Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-ß-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-ß-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2;
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;
n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2;
Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
D-Phe-c(Cys-His-D-Phe-hArg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Bip-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-Phe-hArg-Bip-ß-Ala-D-Cys)-Thr-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;
Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-ß-Ala-Lys)-NH2;
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;
Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;
Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-ß-Ala-Lys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-OH;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;
Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;
Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH;
Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;
Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;
Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;
Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-ß-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;
Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;
Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;
Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;
Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;
Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2;
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;
Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-Doc-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-NH2;
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(ß-Ala)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-Gln-(Arg)5-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-Gln-Lys-(Arg)5-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)4-Gln-Arg-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Aib-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)3-Gln-(Arg)2-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Gln-(Lys)2-(Arg)5-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)5-Gln-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Arg-Asp-ß-Ala-Tyr-Gly-(Arg)6-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-Arg-(Lys)2-Arg-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-Arg-(Lys)2-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Gly-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)2-Lys-(Arg)2-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Arg-Lys-(Arg)3-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2; ;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-ß-Ala-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-ß-Ala-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-Phe-Arg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-ß-Ala-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-ß-Ala-D-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-ß-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-Doc-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-ß-Ala-D-Cys)-Thr-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-ß-Ala-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(ß-Ala)2-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)3-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-Doc-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-Tyr-Gly-(Arg)5-Gln-(Arg)4-NH2;
Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-(Doc)2-(Arg)5-Gln-(Arg)4-NH2;
Ac-c(Cys-Glu-His-D-4-Br-Phe-Arg-Trp-Gly-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-1-Nal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-Bal-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-ß-Ala-Cys)-(Pro)2-Lys-Asp-NH2;
Ac-c(Cys-Glu-His-D-2-Nal-Arg-2-Nal-Aib-Cys)-(Pro)2-Lys-Asp-NH2;
c[Гидантоин(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(hCys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Cys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(hCys-D-Ala))-His-D-2-Nal-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;
c[Гидантоин(C(O)-(Asp-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;
c[Гидантоин(C(O)-(Asp-His))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-His))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A3c))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A5c))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A6c))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A3c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-A6c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин (C(O)-(Asp-A5c))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Aic))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Apc))-D-Phe-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин-(C(O)-(Asp-Aic))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин-(C(O)-(Asp-Apc))-D-2-Nal-Arg-Trp-Lys]-NH2;
c[Гидантоин(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Orn]-NH2;
c[Гидантоин(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dab]-NH2;
c[Гидантоин(C(O)-(Glu-D-Ala))-His-D-Phe-Arg-Trp-Dap]-NH2;
c[Гидантоин(C(O)-(Glu-His))-D-Phe-Arg-Trp-Dap]-NH2;
Гидантоин(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;
Гидантоин(C(O)-(Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Ala-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Aib-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Val-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Ile-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Leu-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Gly))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Arg-Gly))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Ala-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Val-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Nle))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(A6c-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(D-Ala-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Val-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Leu-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Cha-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Aib-Nle))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-Glu-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-D-Arg))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Gly-D-Arg))-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;
Гидантоин(C(O)-(Nle-Ala))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;
c[Гидантоин(C(O)-(Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2,
c[Гидантоин(C(O)-(Nle-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(D-Ala-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Aib-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Val-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Abu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Leu-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Ile-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Cha-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(A6c-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Phe-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Gly-Cys))-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2;
c[Гидантоин(C(O)-(Gly-Cys))-Glu-His-D-Phe-Arg-Trp-Cys]-NH2;
Ac-Tyr-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-2-Nal-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-1-Nal-Arg-c(Cys-D-Ala-His-DPhe-Arg-Trp-Cys)-NH2;
Ac-Phe-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Trp-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-Pff-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
H-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;
Ac-His-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; и
Ac-D-Arg-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2
или их фармацевтически приемлемых солей.
7. Способ по п.6, где указанное соединение представляет собой Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 или его фармацевтически приемлемую соль.
8. Способ по п.6, где указанное соединение представляет собой гидантоин(C(O)-(Arg-Gly))-c(Cys-Glu-His-D-Phe-Arg-Trp-Cys)-NH2 или его фармацевтически приемлемую соль.
9. Способ по любому из пп.1-8, где указанный субъект имеет ожирение, избыточную массу, нормальную массу или является худым.
10. Способ по п.9, где указанный субъект страдает диабетом II типа.
11. Способ по п.1, где указанное периферическое введение является пероральным, подкожным, внутрибрюшинным, внутримышечным, внутривенным, ректальным, трансдермальным или интраназальным.
12. Способ по п.11, где указанное введение осуществляется непрерывно, ежечасно, четыре раза в день, три раза в день, два раза в день, один раз в день, один раз через день, два раза в неделю, один раз в неделю, введением раз в две недели, раз в месяц или раз в два месяца.
RU2012108110/15A 2009-08-05 2010-07-30 Применение меланокортинов для лечения дислипидемии RU2012108110A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
US61/273,488 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
RU2012108110A true RU2012108110A (ru) 2013-09-10

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012108110/15A RU2012108110A (ru) 2009-08-05 2010-07-30 Применение меланокортинов для лечения дислипидемии

Country Status (12)

Country Link
US (2) US20120135923A1 (ru)
EP (1) EP2461681A4 (ru)
JP (1) JP2013501053A (ru)
KR (1) KR20120059520A (ru)
CN (1) CN102548399A (ru)
AU (1) AU2010279719A1 (ru)
BR (1) BR112012002445A2 (ru)
CA (1) CA2769883A1 (ru)
IN (1) IN2012DN01493A (ru)
MX (1) MX2012001513A (ru)
RU (1) RU2012108110A (ru)
WO (1) WO2011017209A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ585131A (en) 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CA2833676C (en) * 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
CA2862444A1 (en) * 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
MA43040A (fr) 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
WO2019219714A1 (en) * 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
JP2008519008A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
JP2009500426A (ja) * 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
PL2286825T3 (pl) * 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
ES2618315T3 (es) * 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
AR066175A1 (es) * 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
NZ585131A (en) * 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity

Also Published As

Publication number Publication date
WO2011017209A1 (en) 2011-02-10
CA2769883A1 (en) 2011-02-10
JP2013501053A (ja) 2013-01-10
BR112012002445A2 (pt) 2015-10-13
MX2012001513A (es) 2012-05-22
CN102548399A (zh) 2012-07-04
AU2010279719A1 (en) 2012-03-01
US20120135923A1 (en) 2012-05-31
EP2461681A4 (en) 2013-04-24
KR20120059520A (ko) 2012-06-08
IN2012DN01493A (ru) 2015-06-05
US20130331324A1 (en) 2013-12-12
EP2461681A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
RU2012108110A (ru) Применение меланокортинов для лечения дислипидемии
AU2020203101B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
Maggi et al. The activity of peptides of the endothelin family in various mammalian smooth muscle preparations
ES2354282T3 (es) Análogos peptídicos inhibidores de la hepatitis c.
RU2014111472A (ru) Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1
FI67539B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptidyl-ng-karboxyl-arginaldehyder
EA201490852A1 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP4779971B2 (ja) ヒストンデアセチラーゼ阻害剤とトポイソメラーゼｉｉ阻害剤とからなる抗腫瘍剤
US10857118B2 (en) Compositions and methods for treating intestinal hyperpermeability
EP3120860A1 (en) Methods for the prevention or treatment of cardiac fibrosis
RU2011105821A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
MX2009007830A (es) Inhibidor de rechazo cronico.
MX2008015337A (es) Metodo y compuesto para el tratamiento de estenosis valvular.
JP2013503110A5 (ru)
RU2012134974A (ru) Стабилизированное соединение гормона роста
Caron et al. Protein digestion and energy homeostasis: How generated peptides may impact intestinal hormones?
EP2714716A1 (en) Matriptase inhibitors and uses thereof against orthomyxoviridae infections
Schiffrin Endothetin: role in hypertension
AU2012286594A1 (en) Modulators of protease activated receptors
RU2693478C1 (ru) Новый пептид и его применение
FI3749353T3 (fi) Nemolitsumabi keskivaikeita–vaikeita hilseilykohtia aiheuttavan atooppisen ihottuman hoidossa
JP5940542B2 (ja) 細胞導入ペプチドと皮膚導入促進剤とを組み合わせた皮膚導入システムおよび美白剤
WO2025254698A1 (en) Orally deliverable non-naturally occurring melanocortin analogs and uses thereof for modulating weight loss
WO2025122385A1 (en) Methods and compositions for reducing scar formation and treating dermatological wounds
CA2598786A1 (en) Composition and method for increasing the anabolic state of muscle cells

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20131121